文献速递血栓与止血

表达Bi8新型单链FVIII模拟抗体的血友病A替代AAV基因治疗

Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody.
PubMed 文献 · Blood · 2025-01-01

研究开发了携带Bi8(一种54.5千道尔顿FVIII模拟抗体)的AAV8-Bi8肝脏靶向基因治疗,在体外可纠正FVIII缺乏血浆至与艾美赛珠单抗相当水平,在FVIII缺陷小鼠中单次给药实现剂量依赖性持久表达、完全纠正出血表型且无毒性或抗药抗体反应。

要点

  • AAV8-Bi8通过4.4千碱基表达盒包装,编码54.5千道尔顿单链FVIII模拟抗体Bi8。
  • 体外Bi8可纠正FVIII缺乏人血浆至与艾美赛珠单抗相当水平。
  • FVIII缺陷小鼠单次给药后呈剂量依赖性持久表达并完全纠正出血表型,无毒性或抗药抗体反应。

核心结论

  • 通过AAV递送FVIII模拟抗体而非截短FVIII转基因,可能为血友病A基因治疗提供更灵活高效的平台。
  • AAV8-Bi8有潜力提供持续终生止血控制,包括已产生FVIII抑制物的患者。

研究设计与样本

  • 研究开发了AAV8-Bi8肝脏靶向基因治疗,编码Bi8新型54.5千道尔顿FVIII模拟抗体。
  • Bi8以紧凑的单链串联单链可变片段形式表达,通过4.4千碱基表达盒包装于AAV8衣壳内。
  • 体外评估Bi8的FVIII模拟活性,并在FVIII缺陷小鼠中单次给药评估体内表达与疗效。

主要发现

  • 体外Bi8显示FVIII模拟活性,有效纠正FVIII缺乏人血浆至与艾美赛珠单抗相当水平。
  • FVIII缺陷小鼠单次给予AAV8-Bi8后呈剂量依赖性持久Bi8表达,出血表型完全纠正,与艾美赛珠单抗治疗组及野生型动物治疗等效。
  • 未观察到毒性或抗药抗体反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent approval of adeno-associated virus (AAV)-based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Muczynski V, Christophe OD, Tanner L, et al. Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody. Blood. 2025. PMID: 40983037. doi:10.1182/blood.2024027709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。